JPWO2020138491A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020138491A5 JPWO2020138491A5 JP2020562548A JP2020562548A JPWO2020138491A5 JP WO2020138491 A5 JPWO2020138491 A5 JP WO2020138491A5 JP 2020562548 A JP2020562548 A JP 2020562548A JP 2020562548 A JP2020562548 A JP 2020562548A JP WO2020138491 A5 JPWO2020138491 A5 JP WO2020138491A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- preventive
- neurodevelopmental
- disorder
- cognitive impairment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims 28
- 239000003814 drug Substances 0.000 claims 27
- 229940124597 therapeutic agent Drugs 0.000 claims 27
- 230000003449 preventive effect Effects 0.000 claims 19
- 208000010877 cognitive disease Diseases 0.000 claims 16
- 208000028698 Cognitive impairment Diseases 0.000 claims 13
- 230000003247 decreasing effect Effects 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 230000000069 prophylactic effect Effects 0.000 claims 8
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 230000001771 impaired effect Effects 0.000 claims 4
- 229960003299 ketamine Drugs 0.000 claims 4
- 239000003826 tablet Substances 0.000 claims 4
- -1 troche Substances 0.000 claims 4
- 230000001755 vocal effect Effects 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000020358 Learning disease Diseases 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 208000029560 autism spectrum disease Diseases 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 239000006071 cream Substances 0.000 claims 2
- 230000001605 fetal effect Effects 0.000 claims 2
- 230000006870 function Effects 0.000 claims 2
- 239000000499 gel Substances 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 201000003723 learning disability Diseases 0.000 claims 2
- 229940040145 liniment Drugs 0.000 claims 2
- 239000000865 liniment Substances 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 230000014759 maintenance of location Effects 0.000 claims 2
- 230000008774 maternal effect Effects 0.000 claims 2
- 230000015654 memory Effects 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 230000035935 pregnancy Effects 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 239000000829 suppository Substances 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 230000003936 working memory Effects 0.000 claims 2
- 208000007415 Anhedonia Diseases 0.000 claims 1
- 206010005885 Blunted affect Diseases 0.000 claims 1
- 206010021703 Indifference Diseases 0.000 claims 1
- 206010041243 Social avoidant behaviour Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018245688 | 2018-12-27 | ||
| JP2018245688 | 2018-12-27 | ||
| PCT/JP2019/051605 WO2020138491A1 (ja) | 2018-12-27 | 2019-12-27 | 神経発達障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020138491A1 JPWO2020138491A1 (https=) | 2020-07-02 |
| JPWO2020138491A5 true JPWO2020138491A5 (https=) | 2023-01-11 |
| JP7483630B2 JP7483630B2 (ja) | 2024-05-15 |
Family
ID=71127068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020562548A Active JP7483630B2 (ja) | 2018-12-27 | 2019-12-27 | 神経発達障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20220110889A1 (https=) |
| EP (1) | EP3903775A4 (https=) |
| JP (1) | JP7483630B2 (https=) |
| WO (1) | WO2020138491A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3043785T1 (sl) | 2013-09-13 | 2022-02-28 | National University Corporation Chiba University | Uporaba R-ketamina in njegove soli kot farmacevtska sredstva |
| JP7548669B2 (ja) | 2018-02-15 | 2024-09-10 | 国立大学法人千葉大学 | 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 |
| AU2019262197B2 (en) | 2018-05-04 | 2024-12-19 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| CN118647595A (zh) | 2021-10-12 | 2024-09-13 | 感知神经科学公司 | R-氯胺酮盐及其使用方法 |
| CA3245931A1 (en) | 2022-03-14 | 2023-09-21 | Perception Neuroscience, Inc. | R-KETAMINE PHARMACEUTICAL FORMULATIONS |
| JP2023152104A (ja) * | 2022-04-01 | 2023-10-16 | 株式会社エル・エスコーポレーション | 認知機能の評価方法、及び、認知機能の評価装置 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19619665C2 (de) | 1996-05-15 | 2001-03-08 | Goedecke Ag | Racemattrennung von Ketamin |
| US20120225949A1 (en) * | 2009-08-14 | 2012-09-06 | Demitri Papalos | Compositions and methods for treating bipolar disorder |
| US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| SI3043785T1 (sl) * | 2013-09-13 | 2022-02-28 | National University Corporation Chiba University | Uporaba R-ketamina in njegove soli kot farmacevtska sredstva |
| CA2936809A1 (en) * | 2014-01-14 | 2015-07-23 | Children's Hospital Medical Center | Compositions comprising ketamine for treating an autism spectrum disorder |
| EP3085366A1 (en) * | 2015-04-22 | 2016-10-26 | Institut du Cerveau et de la Moelle Epiniere-ICM | Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior |
| WO2017180589A1 (en) * | 2016-04-11 | 2017-10-19 | Auspex Pharmaceuticals, Inc. | Deuterated ketamine derivatives |
| JP2020506231A (ja) * | 2017-01-31 | 2020-02-27 | パオロ エル マンフレディ | 神経系の障害並びにその症状及び徴候の処置又は予防のため並びに疾患及び細胞の老化並びにその症状及び徴候に対する細胞保護のための化合物 |
| WO2019065900A1 (ja) * | 2017-09-27 | 2019-04-04 | 国立大学法人千葉大学 | 神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体 |
-
2019
- 2019-12-27 US US17/417,557 patent/US20220110889A1/en active Pending
- 2019-12-27 WO PCT/JP2019/051605 patent/WO2020138491A1/ja not_active Ceased
- 2019-12-27 EP EP19906114.4A patent/EP3903775A4/en active Pending
- 2019-12-27 JP JP2020562548A patent/JP7483630B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020138491A5 (https=) | ||
| US20090258070A1 (en) | Topical LFA-1 antagonists for use in localized treatment of immune related disorders | |
| MA42295B1 (fr) | Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation | |
| CN103338758B (zh) | 叶酸‑雷米普利组合：具细胞保护性、神经保护性及视网膜保护性的眼科组合物 | |
| JP2016528301A5 (https=) | ||
| JP2008513439A (ja) | 発毛を誘導するための組成物および方法 | |
| JP2014502641A5 (https=) | ||
| RU2018101473A (ru) | Депо-препарат, содержащий сложный эфир лимонной кислоты | |
| JP2018520198A5 (https=) | ||
| JP2017518360A5 (https=) | ||
| MA38694A2 (fr) | Dérivés thérapeutiquement actifs d'estratriène-thiazole à substitution azote en position 17 en tant qu'inhibiteurs de la 17bêta.-hydroxystéroïde déshydrogénase | |
| JP2020531511A5 (https=) | ||
| DK2555776T3 (en) | Combination Compositions of Adenosine A1 Agonists and Non-Selective Beta-Adrenoreceptor Blockers to Reduce Intraocular Pressure | |
| RU2010138650A (ru) | Комбинация, включающая паклитаксел, для лечения рака яичников | |
| WO2011116290A1 (en) | Combination compositions of adenosine a1 agonists and carbonic anhydrase inhibitors for reducing intraocular pressure | |
| JP2016537364A5 (https=) | ||
| JP2019534296A5 (https=) | ||
| WO2023278977A1 (en) | Compounds and methods for degrading rcor1, lsd1, hdac1 and hdac2 in the corest | |
| ES2659458T3 (es) | Compuestos de naftaleno para tratar el prurito | |
| JP2011111418A (ja) | 口腔内局所投与に適したウイルス感染予防製剤 | |
| JP2013510845A5 (https=) | ||
| ES2717481T3 (es) | Engrosamiento corneal central reducido mediante el uso de profármacos de ésteres hidrófilos de beta-clorociclopentanos | |
| JP2011522775A5 (https=) | ||
| WO2022207979A3 (en) | Heterocyclic compounds and their use | |
| WO2023137098A1 (en) | Compositions and methods for improving sexual sensory disorders |